PDL Biopharma Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Private

  • Employees
  • 328

Employees

  • Latest Deal Type
  • IPO

  • Latest Deal Amount
  • $96.8M

PDL Biopharma General Information

Description

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia, and Other countries, of which prime revenue is generated from Asia and North America.

Contact Information

Website
www.pdl.com
Formerly Known As
Protein Design Labs, Inc.
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 932 Southwood Boulevard
  • Incline Village, NV 89451
  • United States
+1 (775)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 932 Southwood Boulevard
  • Incline Village, NV 89451
  • United States
+1 (775)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PDL Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. IPO 20-Mar-1997 $96.8M Completed Generating Revenue
1. Early Stage VC Completed Startup
To view PDL Biopharma’s complete valuation and funding history, request access »

PDL Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements, and debt facilities in th
Drug Discovery
Incline Village, NV
328 As of 2022

Redwood City, CA
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PDL Biopharma Competitors (15)

One of PDL Biopharma’s 15 competitors is Coherus Biosciences, a Formerly VC-backed company based in Redwood City, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Coherus Biosciences Formerly VC-backed Redwood City, CA
Hikma Pharmaceuticals Corporation London, United Kingdom
Jubilant Pharmova Corporation Noida, India
Astellas Pharma Corporation Tokyo, Japan
OPKO Health Corporation Miami, FL
You’re viewing 5 of 15 competitors. Get the full list »

PDL Biopharma Patents

PDL Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20090175847-A1 Humanized antibodies to ab (20-42) globulomer and uses thereof Inactive 30-May-2007
US-20110008883-A1 Mammalian cell-based immunoglobulin display libraries Active 01-Nov-2006
US-7700739-B2 Complementary determining regions (cdr); interleukins (il-12) Active 30-Jun-2005
US-20100047245-A1 Complementary determining regions (cdr); interleukins (il-12) Active 30-Jun-2005
US-20100196315-A1 Il-12/p40 binding proteins Active 30-Jun-2005 C07K16/244
To view PDL Biopharma’s complete patent history, request access »

PDL Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PDL Biopharma Investments & Acquisitions (7)

PDL Biopharma’s most recent deal was a PIPE with Evofem Biosciences for . The deal was made on 10-Jun-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Evofem Biosciences 10-Jun-2019 PIPE Pharmaceuticals
Evofem Biosciences 11-Apr-2019 PIPE Pharmaceuticals
Noden Pharma 06-Jul-2016 Merger/Acquisition Pharmaceuticals
Axogen 14-Nov-2014 PIPE Biotechnology
Avinger 22-Apr-2013 Mezzanine Other Devices and Supplies
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

PDL Biopharma ESG

Risk Overview

Risk Rating

Updated November, 02, 2020

29.24 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,189

Rank

Percentile

Pharmaceuticals

Industry

of 901

Rank

Percentile

Biotechnology

Subindustry

of 403

Rank

Percentile

To view PDL Biopharma’s complete esg history, request access »

PDL Biopharma FAQs

  • When was PDL Biopharma founded?

    PDL Biopharma was founded in 1986.

  • Where is PDL Biopharma headquartered?

    PDL Biopharma is headquartered in Incline Village, NV.

  • What is the size of PDL Biopharma?

    PDL Biopharma has 328 total employees.

  • What industry is PDL Biopharma in?

    PDL Biopharma’s primary industry is Drug Discovery.

  • Is PDL Biopharma a private or public company?

    PDL Biopharma is a Private company.

  • What is the current valuation of PDL Biopharma?

    The current valuation of PDL Biopharma is .

  • What is PDL Biopharma’s current revenue?

    The current revenue for PDL Biopharma is .

  • How much funding has PDL Biopharma raised over time?

    PDL Biopharma has raised $96.8M.

  • Who are PDL Biopharma’s competitors?

    Coherus Biosciences, Hikma Pharmaceuticals, Jubilant Pharmova, Astellas Pharma, and OPKO Health are some of the 15 competitors of PDL Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »